Eli Lilly and Company has announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018.
Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1, 2018. Johnson will continue to lead Lilly’s investor relations efforts.
“Phil has been a trusted partner for our shareholders, effectively communicating the company’s results and expectations, while ensuring management’s actions are informed by shareholder input,” Smiley said. “With his external focus and experience in the capital markets, Phil is an ideal candidate to assume this important position and to help guide Lilly’s financial strategy.”
Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas. He has been in his current role since 2007 and before that was vice president, Finance, and chief financial officer for Global Manufacturing and Quality. Prior to joining Lilly, Johnson worked for six years in investment banking and management consulting in the U.S. and Europe.
Source: Eli Lilly and Company
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
